High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies

We developed a new high-dose combination of infusional gemcitabine with busulfan/melphalan for lymphoid tumors. Gemcitabine dose was escalated by extending infusions at a fixed rate of 10 mg/m(2)/min in sequential cohorts, in daily, 3-dose or 2-dose schedules. Each dose immediately preceded busulfan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nieto, Y, Thall, P, Valdez, B, Andersson, B, Popat, U, Anderlini, P, Shpall, EJ, Bassett, R, Alousi, A, Hosing, C, Kebriaei, P, Qazilbash, M, Gulbis, A, Chancoco, C, Bashir, Q, Ciurea, S, Khouri, I, Parmar, S, Shah, N, Worth, L, Rondon, G, Champlin, R, Jones, RB
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010147/
https://ncbi.nlm.nih.gov/pubmed/22643322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2012.05.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars